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Respiratory symptoms relate to physiological
changes and inflammatory markers
reflecting central but not peripheral airways.
A study in 60-year-old ‘healthy’ smokers
and never-smokers
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The aim of this study was to evaluate the relationship between respiratory symptoms, lung function and
inflammatory markers in ‘healthy’ smokers.
The study population was recruited from an epidemiological study with subjects of the same age, 60 years. Only
smokers who considered themselves healthy (n¼58) and a random sample of never-smokers (n¼34) were
investigated. All subjects underwent lung function tests—spirometry, carbon monoxide transfer (DLCO) and the
single-breath N2 method (N2 test)—together with high-resolution computed tomography (HRCT). A flexible
bronchoscopy with a bronchoalveolar lavage (BAL) was performed in 30 smokers and 18 never-smokers. Bronchial
biopsies were also taken.
Smokers who reported non-specific respiratory problems, chronic bronchitis and wheezing in a symptom
questionnaire had a lower forced expiratory volume in 1 sec (FEV1), FEV% and specific airway conductance
(sGaw), lung function tests supposed to reflect the more central airways, than smokers without respiratory
symptoms. A limited number of smokers with occasional non-specific respiratory problems also had more cytotoxic
T cells (CD8) in bronchial biopsies. No differences were found in DLCO and the N2 test, lung function tests
supposed to reflect the more peripheral airways including the alveoli, HRCT-diagnosed emphysema or
inflammatory markers in blood and BAL between smokers with and without respiratory symptoms.
It is concluded that even when smokers consider themselves ‘healthy’ they have mild symptoms that are related
more to physiological changes and inflammatory markers that may reflect events in the central airways than to
changes that may reflect events in the peripheral airways.
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Many smokers develop chronic bronchitis, and at least
15% will develop chronic obstructive pulmonary disease
(COPD) (1,2). It would be desirable to diagnose COPD
early, before the patient has become seriously handicapped.
Chronic obstructive pulmonary disease is an insidious
disease in its early phases, however, and it is dicult to
identify persons at risk of developing severe COPD. TheReceived 29 February 2000 and accepted in revised form 26
September 2000. Published online 11 December 2000.
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0954-6111/01/010040+08 $35?00/0importance of symptoms in early phases of the disease has
not been well documented.
Many investigators have tried to identify which pulmon-
ary function test is the most sensitive for predicting the
future development of COPD. Burrows et al. found that a
decreased forced expiratory volume in 1 sec/forced vital
capacity (FEV1/FVC) ratio in male smokers was almost
uniformly associated with a high rate of decline in FEV1
(3). Carbon monoxide transfer (DLCO) below 85% of
predicted level was found to be a significant predictor of the
all-cause mortality rate in the U.S. population (4). It has
not yet been shown whether a low DLCO is a risk factor for
developing, or dying from, COPD. Some evidence suggests
that a reduced DLCO predicts a future decline in FEV1 (5).
The single-breath N2 test (N2 test) has been found to be
sensitive for detecting small-airways disease in smokers and
for predicting the rate of decline in FEV1 (6–8).# 2000 HARCOURT PUBLISHERS LTD
FIG. 1. Subject recruitment for the present study from the
WHO study ‘Men born in 1933 in Go¨teborg’.
RESPIRATORY SYMPTOMS AND INFLAMMATORY MARKERS IN HEALTHY SMOKERS 41Smoking is the most important risk factor in COPD (9).
Smokers have a greater number of respiratory symptoms,
such as cough, increased sputum production, wheezing and
dyspnoea compared with non-smokers (1,10,11). Many
years ago, Fletcher et al. stated that a diagnosis of chronic
bronchitis was not a risk factor for developing COPD (12).
More recent studies have shown that chronic hypersecre-
tion is independently related to decreased lung function and
to death from obstructive lung disease (13–15).
Smokers have a neutrophil inflammation in the bronchii,
as reflected in bronchoalveolar lavage (BAL) (16–18). This
inflammation is more exaggerated in smokers with
decreased lung function (17,19,20). ‘Healthy’ smokers also
have a neutrophil inflammation in the bronchii that is
related to a fall in DLCO but not to a fall in FEV1 (21). In
about 40% of these smokers, high-resolution computed
tomography (HRCT) shows emphysematous lesions related
to a fall in transfer factor (DLCO/VA) (22) and to an
increase in the neutrophil-specific inflammatory marker
HNL in BAL (21,23).
Several studies show a possible involvement of lympho-
cytes in COPD (24–27). This lymphocytic inflammation in
the bronchial mucosa is characterized by a predominance of
CD8+T lymphocytes related to a decrease in FEV1 (27,28).
‘Healthy’ smokers had a similar correlation in the bronchial
mucosa related to a small fall in FEV1 (29).
The aim of this study was to evaluate whether there is
any respiratory symptom in smokers with preclinical
disease (subjects who regard themselves as ‘healthy’) and
lung function changes, high-resolution computed tomogra-
phy (HRCT) findings or inflammatory markers believed to
indicate the presence of COPD/emphysema. This was done
by comparing respiratory symptoms with lung function,
emphysema score and inflammatory markers. All subjects
underwent both lung function tests aimed at reflecting the
more central airways [FEV1, specific airway conductance
(sGaw)] and lung-function tests aimed at reflecting the
more peripheral airways including the alveoli (DLCO and
N2-test), together with HRCT to diagnose emphysema.
About 60% of the subjects accepted undergoing a flexible
bronchoscopy, where we obtained bronchial biopsies and
performed bronchoalveolar lavage (BAL).
Material and methods
SUBJECTS
The subjects were recruited from the population study ‘Men
born 1933 in Go¨teborg’ (Fig. 1), a random half of all men
born in 1933 and residing in Go¨teborg in 1983 (n¼1016)
(30). Eight hundred and seventy-nine men in the original
cohort who were still alive and living in Go¨teborg were
recruited for a second examination in 1993. Of the 602
participating men, 532 were evaluated by spirometery. Of
these, 112 were smokers, 198 were never-smokers and 222
were former smokers who had not smoked for at least 1
month. All smokers and a random sample of 60 lifelong
never-smokers were offered a lung examination. Fifty-eight
smokers and 34 never-smokers consented to furtherinvestigations and, of these, 30 smoking and 18 never-
smoking men accepted undergoing a bronchoscopy.
Among those originally included in the study, subjects
were excluded if they had any airway disease for which they
had sought medical attention (n¼11), had a history of
congestive heart failure or unstable angina pectoris (n¼4)
or had any other severe disease (n¼5). Subjects would also
have been excluded if they had scoliosis or other diseases
with thorax deformation, any kind of infection during the 4
weeks preceding the examination or had received corticos-
teroids, N-Acetylcysteine (NAC) or acetylsalicylic acid
(ASA) treatment less than 4 weeks prior to blood tests or
bronchoscopy. No subject was excluded for any of these
reasons. Acetyl salicylic acid treatment was allowed in
subjects with prior myocardial infarction (n¼8). Four
smokers had quit smoking before they came to the
follow-up and were therefore excluded. The rest of the
dropouts were not willing to participate in the study for
various reasons (n¼56). The dropout frequency was equally
distributed among smokers and never-smokers.
Thirty-three out of 58 (57%) were current heavy smokers
(15 cigarettes per day) and 25 out of 58 (43%) were
current light smokers (515 cigarettes per day). The median
number of pack-years was 35 (9–79) years.
Lung function, biopsy findings, lymphocyte sub popula-
tions in BAL and blood, the cytokine pattern in blood and
BAL and emphysematous changes have been described in
earlier papers (21,22,29).
The study was approved by the local Ethics Committee at
Sahlgrenska University Hospital, Go¨teborg, Sweden.
QUESTIONNAIRE
The questionnaire was a modified version of the European
Community Respiratory Health Survey (31). It was divided
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contained items concerned with the level of symptomatol-
ogy, including wheezing, dyspnoea, cough, sputum produc-
tion and one non-specific question, ‘Do you ever have
trouble with your breathing?’ if the answer to this last
question was yes, the subject was asked to indicate whether
this was continuously/repeatedly/only rarely. The subjects
were to deny having asthma. The second section contained
items concerned with smoking habits. In the third section,
the subjects were asked about other diseases and con-
comitant medication. The subjects answered the question-
naire before any lung function test, bronchoscopy or
HRCT was done. All subjects answered the questionnaire
except for one smoker and one never-smoker.
LUNG-FUNCTION TESTS
Lung volumes and sGaw were obtained by a flow-
displacement body plethysmograph (SensoriMedics 2200,
Bilthoven, The Netherlands). Forced expired volume in
1 sec and vital capacity (VC) were obtained on a water-
sealed, regularly calibrated bell spirometer. Carbon mon-
oxide transfer was assessed by the single breath method
with standard equipment (SensorMedics 2200. Bilthoven,
The Netherlands). The slope of phase III was obtained by
the single breath N2 method (32). For lung volumes and
spirometry the European Coal and Steel Community
(ECSC) reference values were used (33) and for DLCO
and DLCO/VA the reference values according to Salorinne
were used (34). For single breath N2-test the authors’ own
data, from earlier studies were used (35).
FIBRE-OPTIC BRONCHOSCOPY AND
SAMPLE COLLECTIONS
Pre-medication was given with diazepam 5mg orally
followed by 0?5ml morphine-scopolamine intra-muscu-
larly. If the person had a history of kidney or gall bladder
disease, petidine 75mg intramuscularly and atropine 0?5mg
subcutaneously were given instead of morphine-scopola-
mine. Additional diazepam (2?5–5mg) was given intrave-
nously during the bronchoscopic procedure in some cases.
All individuals were given terbutalin 0?25mg/dose 263 in
nebulizer to avoid unexpected bronchoconstriction during
the procedure. Local anaesthesia was given initially with
1% tetracaine-spray in the mouth and laryngeal tract.
Additional anaesthesia was applied through the broncho-
scope channel for the lower respiratory tract. The
bronchoscopy was performed transorally with an Olympus
flexible fibre-optic bronchoscope (Tokyo, Japan). The
subjects were examined in a supine position by one
experienced bronchoscopist. Oxygen saturation was mea-
sured with an Ohmeda Pulse Oximeter (Louisville, U.S.A.)
during the bronchoscopy and supplemental oxygen was
given at a rate of 2–3 lmin71 through a nasal catheter when
needed.
All bronchoscopies were made between 08.00 hours and
10.00 hours. Bronchial biopsies (3–4 biopsies/subject) were
taken with an alligator forceps from subsegmental septa inthe lower left lobe. The biopsies were gently removed from
the forceps, immediately placed in a sterile moistened
chamber and transported to the laboratory for further
processing. Fourteen out of 30 biopsies from the smokers
and 10 out of 18 biopsies from the never-smokers were
evaluable. In five out of 30 smokers and in one out of 18
never-smokers, no biopsy material was obtainable. In 11
out of the remaining 25 smokers and seven out of the
remaining 17 never-smokers, the biopsy samples were not
histologically evaluable. These subjects, not analysed with
immunohistochemistry, did not differ in sex, age or lung
function, except for DLCO (% pred.) in never-smokers,
compared with those evaluated (29). For detailed descrip-
tion of the immunohistochemistry method used, the
authors refer to an earlier paper (29).
Bronchoalveolar lavage was performed as follows; with
the bronchoscope in a wedged position 3650ml of
phosphate buffered saline (PBS) were instilled into the
middle lobe and after each portion of PBS, suction was
done into siliconized bottles placed on ice. The samples
were immediately transported to the laboratory for
analysis. On the basis of earlier results (29), T lymphocytes
(CD3+), T helper/inducer (TH) lymphocytes (CD3+4+),
T cytotoxic/suppressor (TC) lymphocytes (CD3+8+), and
T lymphocyte activation markers CD28+, CD3+57+ and
CD3+69+, together with the marker for Natural killer
(NK) cells (CD3-56+16+) both in BAL and in blood were
chosen for analysis. Bronchoalveolar lavage was performed
during all bronchoscopies. In 11 out of 30 smokers and in
one out of 18 never-smokers, the BAL FACScan analysis
was impossible to interpret due to debris and dead cells. For
a detailed description of the flow cytometry method and the
analysis of inflammatory markers (HNL, MPO, IL-8, IL-
1b, lysozyme, CC-16), earlier papers are referred to (21,29).
HIGH-RESOLUTION TOMOGRAPHY
The examination was performed with a Picker PQ 2000.
The subjects were examined in a supine position and at full
inspiration. The entire thorax was scanned with a slice
thickness of 1?5mm and 3mm inter-slice distance. Ex-
posure data were 130 kV and 200mA. The images were
reconstructed with the sharp aligorithm of Picker and six
images were copied to each 14@617@ film. Window width
was set at 1499 HU and the level at 7400 HU.
The images were analysed from the hard copies by two
experienced chest radiologists independently, without
knowledge of whether the subject was a smoker or not.
The radiologists analysed each slice in each lung. The
diagnosis of emphysematous changes was based on findings
of areas of low attenuation and/or the presence of
stretched, narrowed vessels. The degree of emphysema
was scored as 0=no emphysema, 1=1–25% of the
parenchymal area was involved, 2=26–50% involvement,
3=51–75% involvement and 4=more than 75%. The
scores for each slice and lung were added and the sum
divided by the number of slices. In this way a score of
total lung involvement could be calculated and the
individual observer’s evaluations compared. To evaluate
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weighted kappa-analysis was used, which was 0?78 (36).
STATISTICAL METHODS
The distribution of values for T lymphocytes and lympho-
cyte subsets in blood and BAL, as well as soluble
inflammatory markers in the same compartments, are
presented with their mean and range. The distribution for
T cells in the bronchial mucosa are presented with median
and range. For lung-function variables, mean and standard
deviation (SD) are presented. The w2-test or Fischers’ exact
test, were used for the comparison of the proportions of
different symptoms in the groups of smokers and never-
smokers. The Mann–Whitney U-test was used for the
comparison of different inflammatory markers in smokers
with and without different symptoms. All tests were two-
sided and P-values lower than 0?05 were regarded as
significant. Abacus Concepts, Stat View 4?51 (Abacus
Concepts, Inc., Berkely, CA, U.S.A.) was used as a
statistical package. A professional statistician was also
consulted.
Results
PREVALENCE OF RESPIRATORY
SYMPTOMS
Although the smokers considered themselves healthy, both
the diagnosis of chronic bronchitis and the respiratory
symptoms of wheezing and non-specific trouble with
breathing (‘Do you ever have trouble with your breathing?’)
were common. Twenty-one of the 57 smokers (37%) gave a
positive answer to this question, compared with nine of 33
never-smokers (27%) (P¼0?23). Among these smokers,
none had this symptom always, 3/21 had it repeatedly and
18/21 had it occasionally. Among the never-smokers that
stated they had this symptom, most had it occasionally
(5/9).
Fourteen of 57 smokers were classified as having chronic
bronchitis (25%). Respiratory symptoms were classified as
chronic bronchitis by the presence of chronic or recurrent
increases in bronchial secretions sucient to cause expec-
toration, present on most days for a minimum of 3 months
a year, for at least 2 successive years (37). Never-smokers
with symptoms classified as chronic bronchitis (n¼3) were
excluded before the start of the study.
Wheezing was present in 22 of 57 (39%) of the smokers
and in four of 33 (12%) of the never-smokers (P¼0?0001).
Questions about dyspnoea ‘sometimes at rest’, sometimes
at exercise’, ‘sometimes at night’, resulted in very few
positive answers and did not show significant differences
between smokers and never-smokers.
As this study was aimed at evaluating the relationship
between respiratory symptoms in smokers with a decrease
in lung function, emphysema or inflammatory markers,
only the data in smokers was chosen to be presented here.Furthermore, the positive observations in never-smokers
were too few for statistical analysis.
RELATIONSHIP BETWEEN RESPIRATORY
SYMPTOMS AND PACK-YEARS
Smokers that answered yes to ‘Do you ever have trouble
with your breathing?’ and those who had chronic bron-
chitis, did not differ in pack-years as compared with
smokers without these symptoms. Smokers with wheezing
had significantly more pack-years as compared with
smokers without this symptom [mean 38 (range 12–79) vs.
31 (9–56), P50?001].
RELATIONSHIP BETWEEN RESPIRATORY
SYMPTOMS AND LUNG-FUNCTION TESTS
Smokers that answered yes to ‘Do you ever have trouble
with your breathing?’ had significantly lower FEV1 and VC
than smokers that denied having this symptom (Table 1).
Smokers with chronic bronchitis also had significantly lower
FEV1, FEV% and SGaw than smokers without this
symptom (Table 1). Smokers with wheezing had signifi-
cantly lower FEV1, FEV% and SGaw than smokers without
this symptom (Table 1). There was no significant relation
between respiratory symptoms and DLCO or the N2 test.
RELATIONSHIP BETWEEN RESPIRATORY
SYMPTOMS AND BIOPSY FINDINGS
Smokers that answered yes to ‘Do you ever have trouble
with your breathing?’ had significantly more CD8+T cells
than those who denied this symptom (Table 2). There were
no other relations between other respiratory symptoms and
T cells or T cell sub-populations in bronchial biopsies.
RELATIONSHIP BETWEEN RESPIRATORY
SYMPTOMS AND LYMPHOCYTE SUB-
POPULATIONS IN BLOOD AND BAL
Smokers that answered yes to ‘Do you ever have trouble
with your breathing?’ had a significantly higher expression
of the T cell activation marker CD69+ in blood as
compared to smokers without this symptom— [0?12 (0–
0?85) vs. 0?02 (0–0?09]6109/l, P¼0?004. There was no
difference in any other lymphocyte sub-population [CD3+,
CD3+4+, CD3+8+, CD3+28+, CD3+57+,
CD3+69+ (in BAL), CD3-56+16+] between the two
groups in blood or BAL.
Smokers with chronic bronchitis (CB) had a significantly
lower expression of the T cell activation marker, CD28+
[38% (31–54%), vs. 61% (24–87%), P¼0? 045] in BAL, as
compared with smokers without CB. There was no
difference in any other lymphocyte sub-population
[CD3+, CD3+4+, CD3+8+, CD3+28+ (in blood),
CD3+57+69, CD3756+16+] between the two groups in
blood or BAL.
TABLE 1. Symptoms and lung-function tests in smokers
‘Ever have problems with your
breathing?’
Chronic bronchitis Wheezing
Yes
(n¼21)
No
(n¼35)
P Yes
(n¼14)
No
(n¼44)
P Yes
(n¼22)
No
(n¼36)
P
TLC (% pred.) 94+12 99+14 n.s. 98+12 97+13 n.s. 98+14 95+12 n.s.
RV (% pred.) 120+30 114+34 n.s. 128+36 112+30 n.s. 124+32 102+24 0?02
VC (% pred.) 82+10 92+14 0?01 83+10 90+14 n.s. 86+12 90+14 n.s.
FEV1 (% pred.) 85+13 100+17 0?001 85+11 97+17 0?01 90+16 99+15 0?03
FEV% 71+8 75+7 n.s. (P¼0?05) 70+7 75+7 0?04 72+8 76+6 0?03
sGaw 2?0+1?2 2?5+1?4 n.s. 1?6+0?8 1?6+0?8 0?01 1?8+1?1 2?9+1?5 0?004
N2 test (% pred.) 200+90 183+83 n.s. 206+78 183+86 n.s. 184+50 172+78 n.s.
DLCO (% pred.) 84+14 82+16 n.s. 83+14 82+16 n.s. 83+12 83+17 n.s.
DLCO/VA (% pred.) 85+18 79+15 n.s. 81+86 82+16 n.s. 82+16 83+17 n.s.
Data are presented as mean and standard deviation, P-value according to Mann–Whitney’s U-test
TABLE 2. Respiratory symptoms in relation to biopsy findings in smokers
‘Ever have problems with your breathing?’
Yes [n¼6 (22)] No [n¼7 (35)] P
Lymphocyte markers
T lymphocytes CD3 Epithelium 451 (206–593) 411 (84–911) n.s.
CD3 Lamina propria 408 (43–744) 184 (0–659) n.s.
T helper CD4 Epithelium 158 (0–365) 139 (0–384) n.s.
CD4 Lamina propria 161 (19–518) 41 (0–336) n.s.
T cytotoxic CD8 Epithelium 362 (295–700) 284 (121–625) n.s.
CD8 Lamina propria 272 (169–417) 98 (13–312) 0?02
Activation marker CD69 Epithelium 172 (0–307) 62 (0–396) n.s.
CD69 Lamina propria 120 (0–222) 10 (0–194) n.s.
Data are presented as median and range, P-value according to Mann–Whitney’s U-test
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sub-population (CD3+, CD3+4+, CD3+8+,
CD3+28+, CD3+57+, CD3+69+, CD3-56+16+),
compared with smokers without wheezing.
RELATIONSHIP BETWEEN RESPIRATORY
SYMPTOMS AND SOLUBLE
INFLAMMATORY MARKERS IN BLOOD
AND BAL
Smokers that answered yes to ‘Do you ever have trouble
with your breathing?’ did not differ in any soluble
inflammatory marker measured in serum or BAL compared
with smokers without this symptom.
Smokers with chronic bronchitis had higher HNL [200
(140–320) vs. 160 (80–301), P¼0?02] and lysozyme [1570
(920–2120 vs. 1360 (790–2660), P¼0?03] in serum ascompared with smokers without CB. There was no
difference in BAL between the groups.
Smokers with wheezing also had higher HNL [180 (100–
320) vs. 150 (80–220), P¼0?03] and lysozyme [1640 (1040–
2660) vs. 1250 (790–1770), P¼0?004] in addition to
myeloperoxidase (MPO) [280 (170–490) vs. 220 (120–310),
P¼0?04] in serum, compared with smokers without this
symptom. There was no difference in BAL between the
groups.
RELATIONSHIP BETWEEN RESPIRATORY
SYMPTOMS AND EMPHYSEMA SCORE
Smokers with different respiratory symptoms such as
occasional non-specific respiratory problems, chronic bron-
chitis and wheezing, did not differ in their emphysema score
compared with smokers without these symptoms.
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SYMPTOMS, BIOPSY FINDINGS AND LUNG
FUNCTION
Smokers with decreased FEV1 had a related increase in
CD8+ T cells in the lamina propria compartment, as
previously published (29). Smokers with both decreased
FEV1 and increased CD8+cells answered positively to the
question ‘Do you ever have trouble with your breathing?’
more often than smokers with normal lung function and
CD8+ levels (Fig. 2).
Discussion
To the authors knowledge, no other study has investigated
respiratory symptoms in smoking subjects chosen on the
basis of being ‘healthy’, i.e. they have not sought medical
attention due to any bronchial or pulmonary disease. As
previously reported, these individuals had both decreased
lung function, expressed as decreased FEV1 and DLCO, as
well as an increased N2 test, and 44% also had emphyse-
matous lesions on HRCT (21,22). Despite feeling healthy,
they reported symptoms which they obviously considered
to be part of their ‘normal’ condition. Smokers with
occasional non-specific respiratory problems, chronic bron-
chitis symptoms and wheezing had decreased lung-function
tests, e.g. FEV1, FEV% and sGaw supposed to mainly
reflect the central parts of the airways. Smokers with
occasional non-specific respiratory problems also had more
CD8+ cells in bronchial biopsies. No important differ-
ences were found between smokers with and without
respiratory symptoms in other tests, such as DLCO and
the N2 test—supposed to mainly reflect the more peripheral
parts of the airways (including the alveoli)—in HRCT-
diagnosed emphysema or inflammatory markers in BAL.
In contrast to what the authors had expected, no
difference in neutrophil-associated soluble inflammatory
markers in BAL was found between smokers with and
without respiratory symptoms (17,18,38,39). This may beFIG. 2. The relationship between the respiratory symptom
‘Do you ever have trouble with your breathing — rarely!’
(&:yes; *:no), biopsy findings (CD8+ cell/profiles
mm217) and lung function [FEV1 (% pred.)].because BAL is thought to mainly reflect events in the
peripheral parts of the airways including the alveoli, while
respiratory symptoms belonging to chronic bronchitis and
wheezing might reflect events in the more central airways.
However, in the present study, smokers with chronic
bronchitis or wheezing had increased serum levels of
HNL and lysozyme and, for wheezing, increased serum
levels of MPO. These soluble inflammatory markers in
serum may reflect events in the more central airways or may
be a marker of smoking (21). In BAL and blood, small
differences in a few T cell activation markers were found
between smokers with and without respiratory symptoms
although these were of questionable biological significance.
Thus, it seems that respiratory symptoms in ‘healthy’
smokers reflects inflammation in central airways but not in
peripheral airways.
Several studies have demonstrated a relationship between
a decrease in FEV1 and an increase in CD8+ T cells in
bronchial biopsies from the subsegmental airways of
smokers, i.e. relatively central airways. This relationship
has been seen in both ‘healthy’ smokers and smokers with
known chronic bronchitis and/or COPD (27–29). In this
study in smokers with only mild symptoms, it was found
that these mild symptoms were more prevalent in subjects
with decreased FEV1 and increased CD8+T cells. Even
though the number of subjects was small, it underscores the
importance of the relationship between FEV1 and CD8+
cells and gives a clinical correlate. It further indicates that
the increase in CD8+ cells could be an early finding in
smokers’ airway disease.
No relationship between respiratory symptoms and
emphysema score was found. It is known from earlier
studies that mild emphysema, a peripheral event, may affect
lung parenchyma without subjects having respiratory
symptoms (22,40,41). Non-specific respiratory symptoms
are probably not signs of mild emphysema.
The present findings are consistent with a hypothesis that
smokers’ airway disease includes two separate processes, a
more centrally localized bronchitis and a more peripheral
alveolar destructive process. The more centrally localized
bronchitis is mainly the result of a lymphocytic inflamma-
tion (28). It seems to give respiratory symptoms early in the
process, in accordance with the present data where
symptomatic subjects seemed to have more lymphocytic
inflammation. The alveolar destructive process is the result
of a more peripheral neutrophil-dominated inflammation
(21,42) and causes fewer respiratory symptoms early in the
process, as neutrophilic changes locally were less related to
symptoms. These findings may explain why some patients
have only mild respiratory symptoms despite severely
impaired lung function and emphysema. It may be possible
to develop severe emphysema without any obvious
respiratory symptoms, in the absence of more centrally
localized bronchitis.
In conclusion, mild respiratory symptoms are observed in
smokers that consider themselves ‘healthy’. These symp-
toms are related to an impaired FEV1 and increased levels
of CD8+cells in bronchial biopsies and probably reflect a
more centrally localized bronchitis. In contrast, early
emphysematous changes and signs of peripheral airways
46 A. EKBERG-JANSSON ET AL.disease, reduced DLCO and an increased N2 test, seem not
to be reflected in respiratory symptoms.
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